ArticleJournal of experimental & clinical cancer research : CR2018
(Arg)
Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Corynoxine Inhibits Tumor Growth via Targeting NQO1 and Modulating the PTPA-NQO1/PP2A Switch to Activate PP2A.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Zebrafish frk Gene Knockout Shows Social Impairments Relevant to Autism and Delays Brain Development by Increasing Cell Proliferation.Autism research : official journal of the International Society for Autism Research · 2026Article
- Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy.Journal of nanobiotechnology · 2026Article
- CoDIAC: A comprehensive approach for interaction analysis provides insights into SH2 domain function and regulation.Science signaling · 2025Article
- Bacillus velezensis MZ09 alleviates DSS-induced colitis in piglets by remodeling the intestinal microbiota activating the SCFAs-GPR43-STAT3 pathway and suppressing NLRP3 inflammasome-mediated pyroptosis.Journal of animal science and biotechnology · 2025Article
- CoDIAC: A comprehensive approach for interaction analysis reveals novel insights into SH2 domain function and regulation.bioRxiv : the preprint server for biology · 2025Article
- Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer.Cell death & disease · 2023Article
- Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis.Theranostics · 2022Article
- Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders.Protein science : a publication of the Protein Society · 2021Article
- Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.Clinical and translational medicine · 2021Article
- miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer.Journal of ovarian research · 2021Article
- Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.Cell death & disease · 2019Article
- Article
- N-acetylcysteine decreases malignant characteristics of glioblastoma cells by inhibiting Notch2 signaling.Journal of experimental & clinical cancer research : CR · 2019Article
- [Design and synthesis of imidazo-fused heterocycles derivatives and their anti-tumor activity against breast cancer in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMelanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows potent antitumor ability by replacing natural SH2-containing proteins and blocking multiple pY-based signaling pathways. Polyarginine (Arg)
methods(Arg)
resultsOur data showed that (Arg)
conclusions(Arg)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.